Artesunate induces G0/G1 cell cycle arrest and iron-mediated mitochondrial apoptosis in A431 human epidermoid carcinoma cells.

abstract：:Advanced stage neuroblastoma is a very aggressive pediatric cancer with limited treatment options and a high mortality rate. Glycogen synthase kinase-3β (GSK-3β) is a potential therapeutic target in neuroblastoma. Using immunohistochemical staining, we observed positive GSK-3β expression in 67% of human neuroblastomas...

journal_title：Anti-cancer drugs

authors： Ugolkov AV,Bondarenko GI,Dubrovskyi O,Berbegall AP,Navarro S,Noguera R,O'Halloran TV,Hendrix MJ,Giles FJ,Mazar AP

更新日期：2018-09-01 00:00:00

abstract：:In this study, we investigated the molecular mechanism of doxorubicin (dxr)-induced cytotoxicity on Jurkat cells - a model cell of human acute lymphoblastic leukemia - under normoxic (20% O2) and hypoxic (5% O2) conditions. Using in-cell western analysis, immunofluorescence, flow cytometry analysis, and biochemical in...

journal_title：Anti-cancer drugs

authors： Mendivil-Perez M,Velez-Pardo C,Jimenez-Del-Rio M

更新日期：2015-07-01 00:00:00

abstract：:We have established estrogen-independent and antiestrogen-resistant cell lines from hormone-dependent MCF-7 breast cancer cells by long-term culture in the absence of estrogen, or in the presence of antiestrogen toremifene, respectively. By using a cDNA microarray we compared gene expression profiles among estrogen-in...

journal_title：Anti-cancer drugs

authors： Pennanen PT,Sarvilinna NS,Ylikomi TJ

更新日期：2009-01-01 00:00:00

abstract：:Based on observations of a discrepancy between 'hypersensitivity' reactions to docetaxel (DT) and the clinical features of allergic reactions, we explored the hypothesis that DT-induced acute hypersensitivity reactions (AHRs) have a non-allergic origin. Forty cancer patients receiving DT and 16 patients receiving othe...

journal_title：Anti-cancer drugs

authors： Ardavanis A,Tryfonopoulos D,Yiotis I,Gerasimidis G,Baziotis N,Rigatos G

更新日期：2004-07-01 00:00:00

abstract：:Dihydroartemisinin (DHA), a semisynthetic derivative of artemisinin, has recently shown antitumor activity in various cancer cells. Its effect on pancreatic cancer is, however, unknown and the mechanism is unclear. The study aims to investigate its antitumor activity and underlying mechanisms in human pancreatic cance...

journal_title：Anti-cancer drugs

authors： Chen H,Sun B,Pan S,Jiang H,Sun X

更新日期：2009-02-01 00:00:00

abstract：:The antitumor effects of a polyamine biosynthetic pathway inhibitor methylglyoxal bis(cyclopentylamidinohydrazone) (MGBCP) on the human hepatocellular carcinoma SK-HEP-1 cell line have been investigated. The growth of these cultured hepatocellular carcinoma cells was inhibited by MGBCP in a dose-dependent manner. Sper...

journal_title：Anti-cancer drugs

authors： Hashimoto Y,Hibasami H,Tamaki S,Kamei A,Ikoma J,Kaito M,Imoto I,Watanabe S,Nakashima K,Adachi Y

更新日期：1999-03-01 00:00:00

abstract：:The type 1 insulin-like growth factor receptor (IGF1R) is overexpressed by many tumors, and mediates growth, motility and protection from apoptosis. Inhibition of IGF1R expression or function has been shown to block tumor growth and metastasis, and enhance sensitivity to cytotoxic drugs and irradiation. Thus the IGF1R...

journal_title：Anti-cancer drugs

authors： Bohula EA,Playford MP,Macaulay VM

更新日期：2003-10-01 00:00:00

abstract：:In recent years, many diseases including cancer and hereditary and viral diseases have been understood at the DNA sequence level. Direct control of the expression level of a specific gene would provide a promising approach for knowledge-based therapy. N-methylpyrrole and N-methylimidazole polyamides are a new type of ...

journal_title：Anti-cancer drugs

authors： Shinohara K,Bando T,Sugiyama H

更新日期：2010-03-01 00:00:00

abstract：:The immunotherapy significantly improved survival of non-small cell lung cancer patients, but it may cause immune-related adverse events, which are severe in less than 10% of cases. We report the case of one patient who developed myositis and myasthenia during nivolumab treatment for metastatic lung squamous carcinoma...

journal_title：Anti-cancer drugs

authors： Veccia A,Kinspergher S,Grego E,Peterlana D,Berti A,Tranquillini E,Caffo O

更新日期：2020-06-01 00:00:00

abstract：:There is growing interest in the discovery of bioactive metabolites from endophytes as an alternative source of therapeutics. Identification of their therapeutic targets is essential in understanding the underlying mechanisms and enhancing the resultant therapeutic effects. As such, bioactive compounds produced by end...

journal_title：Anti-cancer drugs

authors： Hazalin NA,Lim SM,Cole AL,Majeed AB,Ramasamy K

更新日期：2013-09-01 00:00:00

abstract：:Lung cancer remains the leading cause of cancer-associated mortality in China and the world. Increasing numbers of studies have reported that sphingosine kinase 1 (SPK1) is frequently highly expressed in tumors of various origins, including lung cancer, and its high expression contributes toward tumor progression. How...

journal_title：Anti-cancer drugs

authors： Yang Y,Zhao J,Hao D,Wang X,Wang T,Li H,Lv B

更新日期：2019-06-01 00:00:00

abstract：:Trastuzumab, a humanized anti-human epidermal growth factor receptor 2 antibody drug, is the first-line therapy for human epidermal growth factor receptor 2-positive breast and gastric cancer. For breast cancer, the benefit of continuous treatment with trastuzumab after it becomes refractory to first-line therapy has ...

journal_title：Anti-cancer drugs

authors： Shu S,Yamashita-Kashima Y,Yanagisawa M,Nakanishi H,Kodera Y,Harada N,Yoshimura Y

更新日期：2020-03-01 00:00:00

abstract：:Results are summarized for two phase II studies of docetaxel as first-line therapy for advanced squamous cell carcinoma of the head and neck (SCCHN) and one study of docetaxel as second-line therapy for advanced soft tissue sarcomas. In all three studies, docetaxel was administered at a dose of 100 mg/m2 by intravenou...

journal_title：Anti-cancer drugs

authors： Verweij J

更新日期：1995-07-01 00:00:00

abstract：:α-Lipoic acid (α-LA) is a biogenic antioxidant that has been used successfully in the treatment of diabetic polyneuropathy and its application to many oxidative stress-associated chronic diseases has increased. In this study, we investigated the effect of α-LA on colorectal cancer cell growth and its underlying mechan...

journal_title：Anti-cancer drugs

authors： Yoo TH,Lee JH,Chun HS,Chi SG

更新日期：2013-07-01 00:00:00

abstract：:An i.v. formulation of rubitecan (9-nitrocamptothecin) was evaluated in five human solid tumor xenograft models. Rubitecan in IDD-P, a particulate suspension of the insoluble analog, produced significant tumor growth delay in athymic nude mice bearing A375 melanoma, and MX-1 breast, SKMES non-small-cell lung, Panc-1 p...

journal_title：Anti-cancer drugs

authors： Sands H,Mishra A,Stoeckler JD,Hollister B,Chen SF

更新日期：2002-10-01 00:00:00

abstract：:The purpose of the current study was to develop and test a theoretical model that could explain the mechanism of action of gallic acid (GA) in the oral squamous cell carcinoma context for the first time. The theoretical model was developed using bioinformatics and interaction network analysis to evaluate the effect of...

journal_title：Anti-cancer drugs

authors： Guimaraes TA,Farias LC,Fraga CA,Feltenberger JD,Melo GA,Coletta RD,Souza Santos SH,de Paula AM,Guimaraes AL

更新日期：2016-06-01 00:00:00

abstract：:Mistletoe extracts are frequently applied in adjuvant cancer treatment. The mistletoe lectins are especially suggested to mediate an antitumorous effect. During treatment with mistletoe lectin-rich extracts, anti-mistletoe lectin antibodies preferentially of the immunoglobulin G type are produced against mistletoe lec...

journal_title：Anti-cancer drugs

authors： Stein GM,Stettin A,Schultze J,Berg PA

更新日期：1997-04-01 00:00:00

abstract：:A new dosage formulation of 5-fluorouracil incorporated in microspheres (5-FU-MS) was developed for the treatment of peritoneal carcinomatosis. We studied the acute toxicity and side effects of i.p. 5-FU-MS in mice. The 50% lethal dose value for 5-FU-MS was 535.4 mg/kg of 5-FU, which was 2.22 times that of the aqueous...

journal_title：Anti-cancer drugs

authors： Hagiwara A,Sakakura C,Tsujimoto H,Ohgaki M,Imanishi T,Yamazaki J,Sawai K,Takahashi T,Yamamoto A,Muranishi S,Tabata Y,Ikada Y

更新日期：1996-09-01 00:00:00

abstract：:We investigated whether Ukrain modulates the malignant phenotype of clear cell renal cell carcinoma (ccRCC) cells Caki-1, Caki-2, and ACHN treated with four doses (5, 10, 20, and 40 μmol/l) for 24 and 48 h. The epithelial-to-mesenchymal transition markers E-cadherin, β-catenin, and vimentin were analyzed by immunofluo...

journal_title：Anti-cancer drugs

authors： Gagliano N,Pettinari L,Aureli M,Martinelli C,Colombo E,Costa F,Carminati R,Volpari T,Colombo G,Milzani A,Dalle-Donne I,Gioia M

更新日期：2011-09-01 00:00:00

abstract：:At the present time, there is not a standard regimen in upfront metastatic setting for breast cancer. A wide variety of regimens which includes anthracyclines, taxanes, gemcitabine or capecitabine are currently used, however, there is evidence to support the use of many of these drugs in early breast cancer and conseq...

journal_title：Anti-cancer drugs

authors： Estevez LG,Tusquets I,Muñoz M,Adrover E,Rovira PS,Seguí MA,Rodríguez CA,Lescure AR,Ruiz M,Alvarez I,Mata JG

更新日期：2007-08-01 00:00:00

abstract：:Targeted agents such as sunitinib, an oral, multitargeted receptor tyrosine kinase inhibitor, have greatly improved the prognosis for patients with metastatic renal cell carcinoma (mRCC). In this review we analyse data from sunitinib preclinical and clinical studies in detail and consider the key implications for the ...

journal_title：Anti-cancer drugs

authors： Ravaud A,Bello CL

更新日期：2011-06-01 00:00:00

abstract：:Overexpression of the multidrug resistance MDR1 gene product P-glycoprotein and/or the multidrug resistance-associated protein MRP confers multidrug resistance to cancer cells. The pipecolinate derivative VX-710 has previously been demonstrated to reverse MDR1-mediated multidrug resistance at concentrations of 0.5-2.5...

journal_title：Anti-cancer drugs

authors： Germann UA,Ford PJ,Shlyakhter D,Mason VS,Harding MW

更新日期：1997-02-01 00:00:00

abstract：:Clinical empiricism has recognized resistant breast cancer as a privileged target for docetaxel (Taxotere). This worldwide registration will offer medical oncologists the opportunity to develop new indications for docetaxel. Pharmacokinetics, preclinical optimal combination and clinical practice will constitute the ra...

journal_title：Anti-cancer drugs

authors： Armand JP

更新日期：1996-08-01 00:00:00

abstract：:The objective of this study was to evaluate intravesical gemcitabine in high-risk nonmuscle-invasive bladder cancer (NMIBC) refractory to bacillus Calmette-Guérin (BCG). This was a prospective multicentre single-arm trial. Eligible patients were those with high-risk NMIBC refractory to BCG therapy, for which radical c...

journal_title：Anti-cancer drugs

authors： Perdonà S,Di Lorenzo G,Cantiello F,Damiano R,De Sio M,Masala D,Bruni G,Gallo L,Federico P,Quattrone C,Pizzuti M,Autorino R

更新日期：2010-01-01 00:00:00

abstract：:The objective of this study was to determine the safety and efficacy of intravesical novantrone in refractory superficial bladder cancer. The eligibility criteria included proven carcinoma in situ or superficial transitional cell carcinoma of the bladder at stage Ta or T1 that was proven refractory to or in relapse af...

journal_title：Anti-cancer drugs

authors： Sharifi R,Lee M,Clayton M,Lamb D,Siami P,Strub M,Albert D,Sarosdy M

更新日期：1991-04-01 00:00:00

abstract：:There is limited evidence on the costs associated with ipilimumab. We investigated healthcare costs of all Dutch patients with advanced cutaneous melanoma who were treated with ipilimumab. Data were retrieved from the nation-wide Dutch Melanoma Treatment Registry. Costs were determined by applying unit costs to indivi...

journal_title：Anti-cancer drugs

authors： Franken MG,Leeneman B,Jochems A,Schouwenburg MG,Aarts MJB,van Akkooi ACJ,van den Berkmortel FWPJ,van den Eertwegh AJM,de Groot JWB,van der Hoeven KJM,Hospers GAP,Kapiteijn E,Koornstra R,Kruit WHJ,Louwman MWJ,Piersma D,van

更新日期：2018-07-01 00:00:00

abstract：:Schlafen-11 (SLFN11) showed a highly significant positive correlation with the response of topoisomerase inhibitors in cancer cell lines derived from prostate, lung, etc. However, this finding has not been validated in colorectal cancers (CRCs). Although irinotecan (CPT-11), a topoisomerase inhibitor, is one of the mo...

journal_title：Anti-cancer drugs

authors： Tian L,Song S,Liu X,Wang Y,Xu X,Hu Y,Xu J

更新日期：2014-11-01 00:00:00

abstract：:To evaluate the feasibility and pharmacology of intrapleural (IP(L)) administration of paclitaxel, 18 patients with malignant pleural effusions were entered onto a phase I clinical study, 13 were caused by lung cancer. Following an effusion drainage rate of less than 100 ml/24 h and full expansion of the lung, patient...

journal_title：Anti-cancer drugs

authors： Perng RP,Wu MF,Lin SY,Chen YM,Lin JY,Whang-Peng J

更新日期：1997-07-01 00:00:00

abstract：:The effects of vitamin C on the oxidative stress in blood platelets induced by cisplatin were studied. In the presence of vitamin C we measured in blood platelets the production of thiobarbituric acid reactive substances (TBARS), the generation of superoxide radicals (O2*-), other reactive oxygen species (H2O2, single...

journal_title：Anti-cancer drugs

authors： Olas B,Wachowicz B,Buczyński A

更新日期：2000-07-01 00:00:00

abstract：:Treatment of mammalian cells with chemotherapeutic drugs can result in perturbations of nucleotide pools. Monitoring these perturbations in cultured tumor cells from human sources is useful for assessment of the effect of drug therapy and a better understanding of the mechanism of action of these drugs. In this study,...

journal_title：Anti-cancer drugs

authors： Liu X,Zhang CC,Liu Z,Wei L,Liu YJ,Yu J,Sun LX

更新日期：2014-07-01 00:00:00